

**Table S1** Clinicopathological characteristics between EGFR wild type and mutated group

Characteristics	All <sup>†</sup> (N=210)	EGFR wild type (N=99)	EGFR mutant (N=111)	P value
Age at diagnosis, n (%)				0.23
<65 years	99 (47.1%)	51 (51.5%)	48 (43.2%)	
≥65 years	111 (52.9%)	48 (48.5%)	63 (56.8%)	
Sex, n (%)				0.019
Male	78 (37.1%)	45 (45.5%)	33 (29.7%)	
Female	132 (62.9%)	54 (54.5%)	78 (70.3%)	
Smoking status, n (%)				0.002
Never	144 (73.8%)	57 (62%)	87 (84.5%)	
Light	30 (15.4%)	20 (21.7%)	10 (9.7%)	
Heavy	21 (10.8%)	15 (16.3%)	6 (5.8%)	
ECOG, n (%)				0.55
0	94 (44.8%)	41 (41.4%)	53 (47.7%)	
1	113 (53.8%)	57 (57.6%)	56 (50.5%)	
2	3 (1.4%)	1 (1.0%)	2 (1.8%)	
AJCC 8 <sup>th</sup> staging, n (%)				0.006
0	11 (5.2%)	1 (1.0%)	10 (9%)	
IA	136 (64.8%)	63 (63.6%)	73 (65.8%)	
IB	33 (15.7%)	14 (14.1%)	19 (17.1%)	
IIA	16 (7.6%)	12 (12.1%)	4 (3.6%)	
IIB	10 (4.8%)	5 (5.1%)	5 (4.5%)	
IIIA	4 (1.9%)	4 (4.1%)	0	
Tumor size, n (%)				0.029
<4 cm	172 (81.9%)	75 (75.8%)	97 (87.4%)	
≥4 cm	38 (18.1%)	24 (24.2%)	14 (12.6%)	
Histologic grade, n (%)				0.007
Grade 1	106 (50.5%)	40 (40.4%)	66 (59.5%)	
Grade 2	75 (35.7%)	39 (39.4%)	36 (32.4%)	
Grade 3	29 (13.8%)	20 (20.2%)	9 (8.1%)	
Lymphovascular invasion, n (%)				0.29
No	146 (70.2%)	66 (66.7%)	80 (73.4%)	
Yes	62 (29.8%)	33 (33.3%)	29 (26.6%)	
Visceral pleural invasion, n (%)				0.59
No	152 (72.7%)	73 (74.5%)	79 (71.2%)	
Yes	57 (27.3%)	25 (25.5%)	32 (28.8%)	
Tumor necrosis, n (%)				<0.001
No	155 (74.9%)	63 (64.3%)	92 (84.4%)	
Yes	52 (25.1%)	35 (35.7%)	17 (15.6%)	
Bronchial resection margin, n (%)				0.79
<2 cm	58 (28.3%)	28 (29.2%)	30 (27.5%)	
≥2 cm	147 (71.7%)	68 (70.8%)	79 (72.5%)	

<sup>†</sup>, not include 10 of 220 patients who had no result of EGFR mutation. EGFR, epidermal growth factor receptor.

**Table S2** Pattern of relapse and time to recurrence between EGFR wild type and mutated group

	All of recurrence <sup>†</sup> (N=63)	EGFR wild type (N=32)	EGFR mutant (N=31)	P value
Pattern of relapse, n (%)				0.53
Locoregional	16 (25.4%)	7 (21.9%)	9 (29%)	
Distant	43 (68.3%)	22 (68.8%)	21 (67.7%)	
Both locoregional and distant	4 (6.3%)	3 (9.4%)	1(3.2%)	
Intracranial relapse, n (%)	11 (17.5%)	7 (21.9%)	4 (12.9%)	0.35
Median time to recurrence, year (IQR)	2.13 (1.16–3.53)	2.20 (1.23–3.19)	2.06 (1.09–3.87)	0.45

<sup>†</sup>, not include 1 of 64 recurrent patients who had no result of EGFR mutation. EGFR, epidermal growth factor receptor; IQR, inter quartile range.

**Table S3** Number of significant factors between recurrence and non-recurrence

Number of significant factors	All <sup>†</sup> (N=216)	No recurrence (N=156)	Recurrence (N=60)	P value
0 factor, n (%)	94 (100.0)	87 (92.6)	7 (7.4)	<0.001
1 factor, n (%)	59 (100.0)	42 (71.2)	17 (28.8)	
2 factors, n (%)	45 (100.0)	24 (53.3)	21 (46.7)	
3 factors, n (%)	11 (100.0)	3 (27.3)	8 (72.7)	
4 factors, n (%)	7 (100.0)	0	7 (100.0)	

<sup>†</sup>, not include 4 of 220 patients who had missing data of four significant factors.

**Table S4** Five-year recurrence free survival and overall survival of significant prognostic factors and EGFR status

Covariate	5-year RFS	P value	5-year OS	P value
Tumor size <4 cm	76.8%	<0.001	82.5%	0.002
Tumor size ≥4 cm	44.5%		61.9%	
No visceral pleural invasion	80.2%	<0.001	84.5%	0.003
Visceral pleural invasion	45.7%		63.1%	
≥2 cm of bronchial resection margin	78.0%	0.001	82.1%	0.01
<2 cm of bronchial resection margin	56.4%		69.8%	
No tumor necrosis	82.7%	<0.001	86.1%	<0.001
Tumor necrosis	39.6%		56.8%	
Sensitizing EGFR mutation	72.9%	0.52	85.2%	0.02
EGFR wild type	66.4%		73.7%	

EGFR, epidermal growth factor receptor; RFS, recurrence free survival; OS, overall survival.